Dr Charlotte Lemech

Senior Lecturer
Medicine & Health
School of Clinical Medicine

Scientia Clinical Research (SCR) is the first publicly funded purpose built early phase clinical trials centre in UNSW.  We will conduct first-in-human and first-in-patient studies in cancer and across other disciplines, both for novel therapies as well as methods of disease diagnosis and detection.  As part of the Bright Alliance with Prince of Wales Hospital, the Royal Hospital for Women, Sydney Children's Hospital and UNSW, Scientia will provide a research hub and state of the art clinical care.

After completing my FRACP in medical oncology in the SESIAHS network, I worked for 4 years in London at an early phase clinical trials unit, Sarah Cannon Research UK, and completed a MD(res) at University College London.  For my MD(res), I researched biomarker development in endometrial cancer including circulating tumour cells and methylation studies.

I have experience in managing phase I-III clinical trials across a spectrum of tumour streams and molecular targets including immunotherapy, PI3K/Akt, RAF/MEK, FAK, FGFR and others.

  

Phone
93825807
  • Book Chapters | 2011
    Lemech CR; Kristeleit R; Arkenau HT, 2011, 'Novel Oncology Drug Development Strategies in the Era of Personalised Medicine', in Kapetanovic IM (ed.), Drug Discovery and Development - Present and Future, INTECH EUROPE, pp. 43 - 68, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385879400005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
  • Journal articles | 2024
    Armstrong AJ; Geva R; Chung HC; Lemech C; Miller WH; Hansen AR; Lee JS; Tsai F; Solomon BJ; Kim TM; Rolfo C; Giranda V; Ren Y; Liu F; Kandala B; Freshwater T; Wang JS, 2024, 'CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial', Investigational New Drugs, 42, pp. 145 - 159, http://dx.doi.org/10.1007/s10637-023-01410-2
    Journal articles | 2024
    Armstrong AJ; Geva R; Chung HC; Lemech C; Miller WH; Hansen AR; Lee JS; Tsai F; Solomon BJ; Kim TM; Rolfo C; Giranda V; Ren Y; Liu F; Kandala B; Freshwater T; Wang JS, 2024, 'Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial(Investigational New Drugs, (2024), 42, (145-159), 10.1007/s10637-023-01410-2)', Investigational New Drugs, 42, pp. 340 - 341, http://dx.doi.org/10.1007/s10637-024-01444-0
    Journal articles | 2024
    Atkinson VG; Antras JF; Bedard P; Brenner W; Brown J; Lemech CR; Lloyd P; Margolin K; Mathew M; Park JJ; Thomas S; Twardowski P; Gardner H; Prawira A; Coello M; Ebrahimimizadeh W; To MD; Merchant R; Karanam SM; Yavari A; Siu LL; Tawbi HA; Ascierto PA, 2024, 'Abstract CT259: Results from monotherapy dose escalation of MDNA11, a long-acting IL-2 superkine, in a phase 1/2 trial show evidence of single-agent activity in advanced solid tumors', Cancer Research, 84, pp. CT259 - CT259, http://dx.doi.org/10.1158/1538-7445.am2024-ct259
    Journal articles | 2024
    Dorff T; Horvath LG; Autio K; Bernard-Tessier A; Rettig MB; Machiels JP; Bilen MA; Lolkema MP; Adra N; Rottey S; Greil R; Matsubara N; Tan DSW; Wong A; Uemura H; Lemech C; Meran J; Yu Y; Minocha M; McComb M; Penny HL; Gupta V; Hu X; Jurida G; Kouros-Mehr H; Janat-Amsbury MM; Eggert T; Tran B, 2024, 'A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer', Clinical Cancer Research, 30, pp. 1488 - 1500, http://dx.doi.org/10.1158/1078-0432.CCR-23-2978
    Journal articles | 2024
    Frentzas S; Mislang ARA; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG, 2024, 'Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors', Journal for ImmunoTherapy of Cancer, 12, http://dx.doi.org/10.1136/jitc-2023-008037
    Journal articles | 2024
    Gong J; Lemech C; Day D; Shan J; Morris M; Nagrial A; Chen M; Huang X; Zong H; Wang N; Yang Y; Yi T; Li W; Zhuang Z; Li Z; Liu Z; Luo Y; Zhang Y; Zhou H; Shen L, 2024, '576P Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study', Annals of Oncology, 35, pp. S467 - S468, http://dx.doi.org/10.1016/j.annonc.2024.08.645
    Journal articles | 2024
    Hayes AG; Jonker B; Teng C; Lemech C; Killen AJ; Sim HW; McCormack AI, 2024, 'Approach to the Patient: New Era Emerges for Craniopharyngioma Management', Journal of Clinical Endocrinology and Metabolism, 109, pp. 2986 - 2996, http://dx.doi.org/10.1210/clinem/dgae503
    Journal articles | 2024
    Lemech C; Kichenadasse G; Teng C; Nagrial A; Richardson G; Humphries TG; Killen AJ; Joshua A; Liu JJ; Churchill M; Barnett M; Cioffi M; Cosman R, 2024, '676TiP MYE Symphony: A first-in-human study to investigate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the in vivo mRNA CAR therapy, MT-302, targeting TROP2 in adults with advanced epithelial tumors', Annals of Oncology, 35, pp. S528 - S528, http://dx.doi.org/10.1016/j.annonc.2024.08.742
    Journal articles | 2024
    Lemech C; Luke JJ; Falchook GS; Mckean M; Kichenadasse G; Teng C; Vandross AL; Salkeni MA; Atkinson VG; Liu JJ; Kennedy AM; Clark J; Ryan M; Schmidt-Kittler O; Steinhubel D; Wages D; Komarnitsky P; Puzanov I, 2024, '678TiP A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations', Annals of Oncology, 35, pp. S528 - S529, http://dx.doi.org/10.1016/j.annonc.2024.08.744
    Journal articles | 2024
    Lemech C; Sun Y; Nagrial A; Wu X; Morris M; Ning F; Yang J; Pan Y; Cai J; Lu P; Zhang T; Qiu F; Hu C; Zhang M; Liu Z; Han G; Nie J; Teng C; Zhou H; Day D, 2024, '345MO IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study', Annals of Oncology, 35, pp. S360 - S360, http://dx.doi.org/10.1016/j.annonc.2024.08.293
    Journal articles | 2024
    Lemech CR; Zuniga R; Barve MA; Song Y; Zhang J; Zhou K; Zhang L; Shen L; Bishnoi S; Cherng H-JJ; Zhou C; Li W; Wang J; Zhu X; Zhu D; Li F; Shen Z; Yang J, 2024, 'A phase 1a/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas.', Journal of Clinical Oncology, 42, pp. 3023 - 3023, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3023
    Journal articles | 2024
    Tran B; Voskoboynik M; Bendell J; Gutierrez M; Lemech C; Day D; Frentzas S; Garrido-Laguna I; Standifer N; Wang F; Ferte C; Wang Y; Das M; Carneiro BA, 2024, 'A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors', Immunotherapy, 16, pp. 759 - 774, http://dx.doi.org/10.1080/1750743X.2024.2359359
    Journal articles | 2024
    Wahlroos S; Teng C; Tran B; Voskoboynik M; Gan HK; Spencer A; Kudva A; Song M; Lynch K; Yu Z; Desai J; Lemech CR, 2024, 'Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors.', Journal of Clinical Oncology, 42, pp. e15114 - e15114, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e15114
    Journal articles | 2023
    Day D; Park JJ; Coward J; Markman B; Lemech C; Kuo JC; Prawira A; Brown MP; Bishnoi S; Kotasek D; Strother RM; Cosman R; Su R; Ma Y; Yue Z; Hu HH; Wu R; Li P; Tse AN, 2023, 'A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer', British Journal of Cancer, 129, pp. 1608 - 1618, http://dx.doi.org/10.1038/s41416-023-02431-7
    Journal articles | 2023
    Fries L; Formica N; Mallory RM; Zhou H; Plested JS; Kalkeri R; Moldovan I; Patel N; Albert G; Robinson M; Cho I; Chau G; Dubovsky F; Glenn GM; Adams M; Arya M; Athan E; Berger I; Bradley P; Glover R; Griffin P; Kim J; Kitchener S; Klein T; Leah A; Lemech C; Lickliter J; Manning MB; Napier-Flood F; Nugent P; Thackwray S; Turner M, 2023, 'Strong CD4+T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination', Journal of Infectious Diseases, 228, pp. 734 - 741, http://dx.doi.org/10.1093/infdis/jiad163
    Journal articles | 2023
    Fu S; Falchook GS; Barve M; McKean M; Tan TJ; Lemech C; Chee CE; Marina N; Abbadessa G; Meng R; Rotolo F; Wang H; Deng J; Wang W; Wang R; Meniawy T, 2023, 'Abstract 2155: Joint modeling of safety and peripheral mode-of-action (MoA) biomarkers to support RP2D identification in Phase 1 study of SAR444245 (SAR’245) as monotherapy (mono) or combined with pembrolizumab (pembro) in patients with advanced solid tumors', Cancer Research, 83, pp. 2155 - 2155, http://dx.doi.org/10.1158/1538-7445.am2023-2155
    Journal articles | 2023
    Hertzberg M; Kalac M; Cheah CY; Ribrag V; Abrisqueta P; Opat S; Bachy E; Ysebaert L; Qiu L; Yi S; Nishimura N; Lemech C; Bussolari J; Deng C; Lu T; Xiu L; Hemelryck SV; Philippar U; Guo Y; Soete V; Paradinas IS; Fourneau N; Gerecitano J; Morschhauser F, 2023, 'PHASE 1 STUDY OF JNJ‐67856633, A FIRST‐IN‐HUMAN MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)', Hematological Oncology, 41, pp. 131 - 132, http://dx.doi.org/10.1002/hon.3163_88
    Journal articles | 2023
    Kalac M; Hertzberg M; Cheah C; Ribrag V; Abrisquet Acosta P; Opat S; Bachy E; Ysebaert L; Qiu L; Yi S; Nishimura N; Lemech C; Bussolari J; Deng C; Lu T; Xiu L; Van Hemelryck S; Philippar U; Guo Y; Soete V; Soriano I; Fourneau N; Gerecitano J; Morschhauser F, 2023, 'P624: PHASE 1 STUDY OF JNJ-67856633, A FIRST-IN-HUMAN HIGHLY SELECTIVE MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)', HemaSphere, 7, pp. e60782b9 - e60782b9, http://dx.doi.org/10.1097/01.hs9.0000969400.60782.b9
    Journal articles | 2023
    Lee DH; Han J-Y; Lemech CR; Millward M; Roohullah A; Choi JY; Park KE; Kim NY; Im S; Rajasekaran N; Lee S; Moon H; Hwang S; Shin YOUNGKEE; Lee S-H, 2023, 'ABN401 in patients with NSCLC with MET exon 14 (METex14) skipping: Result from the pilot expansion study.', Journal of Clinical Oncology, 41, pp. e21148 - e21148, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e21148
    Journal articles | 2023
    Lemech C; Dredge K; Bampton D; Hammond E; Clouston A; Waterhouse NJ; Stanley AC; Leveque-El Mouttie L; Chojnowski GM; Haydon A; Pavlakis N; Burge M; Brown MP; Goldstein D, 2023, 'Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors', Journal for ImmunoTherapy of Cancer, 11, http://dx.doi.org/10.1136/jitc-2022-006136
    Journal articles | 2023
    Lemech CR; Argent C; Scribner CL; Sharabi A; Daniels R; Appleman JR, 2023, 'Abstract CT180: Activation of innate and adaptive immune response with a clinical stage TLR7 agonist prodrug PRTX007', Cancer Research, 83, pp. CT180 - CT180, http://dx.doi.org/10.1158/1538-7445.am2023-ct180
    Journal articles | 2023
    Lemech CR; Kichenadasse G; Marschner JP; Alevizopoulos K; Otterlei M; Millward M, 2023, 'ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study', Oncogene, 42, pp. 541 - 544, http://dx.doi.org/10.1038/s41388-022-02582-6
    Journal articles | 2023
    Strickler JH; Satake H; George TJ; Yaeger R; Hollebecque A; Garrido-Laguna I; Schuler M; Burns TF; Coveler AL; Falchook GS; Vincent M; Sunakawa Y; Dahan L; Bajor D; Rha SY; Lemech C; Juric D; Rehn M; Ngarmchamnanrith G; Jafarinasabian P; Tran Q; Hong DS, 2023, 'Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer', New England Journal of Medicine, 388, pp. 33 - 43, http://dx.doi.org/10.1056/NEJMoa2208470
    Journal articles | 2023
    Tran B; Millward M; Lemech C; Frentzas S; Day D; Latifi A; Desai J; Wabnitz P; Kearney P; Galkin A, 2023, '1047P AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors', Annals of Oncology, 34, pp. S635 - S635, http://dx.doi.org/10.1016/j.annonc.2023.09.2186
    Journal articles | 2023
    Weickhardt AJ; Frentzas S; Lemech C; Srimani J; Yin J; Trepicchio WL; Gorgun C; Kichenadasse G, 2023, '711TiP A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors', Annals of Oncology, 34, pp. S492 - S492, http://dx.doi.org/10.1016/j.annonc.2023.09.1897
    Journal articles | 2023
    Wynne CJ; Cole A; Lemech C; Wang G; Zhang Y; Chen B; Wang M; Li B; Xia M; Sinclair R, 2023, 'Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study', Dermatology and Therapy, 13, pp. 2357 - 2373, http://dx.doi.org/10.1007/s13555-023-01010-1
    Journal articles | 2022
    Falchook GS; Fu S; Lemech C; Mckean MA; Azad AA; Gan HK; Sommerhalder D; Wang JS; Tan TJY; Chee CE; Barve M; Moser J; Mooney J; Acuff N; Wang R; Marina N; Abbadessa G; Streit M; Ramusovic S; Meniawy T, 2022, '747P Phase I study of SAR444245 (SAR’245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors', Annals of Oncology, 33, pp. S885 - S886, http://dx.doi.org/10.1016/j.annonc.2022.07.873
    Journal articles | 2022
    Lemech C; Argent C; Scribner C; Daniels R; Appleman JR, 2022, 'Abstract CT189: PRTX007, an optimized TLR7 agonist for systemic immunotherapy of cancers: Interim analysis of phase I study in healthy volunteers', Cancer Research, 82, pp. CT189 - CT189, http://dx.doi.org/10.1158/1538-7445.am2022-ct189
    Journal articles | 2022
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM; Adams M; Arya M; Athan E; Berger I; Bradley P; Briskin T; Glover R; Griffin P; Kim J; Kitchener S; Klein T; Leah A; Leelasena I; Lemech C; Lickliter J; Manning MB; Napier-Flood F; Nugent P; Thackwray S; Turner M, 2022, 'Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial', The Lancet Infectious Diseases, 22, pp. 1565 - 1576, http://dx.doi.org/10.1016/S1473-3099(22)00420-0
    Journal articles | 2022
    Pimanda JE; Thoms JAI; Hampton HR; Davidson S; Joshi S; Sarowar CH; Lim XY; Nunez AC; Kakadia PM; Pickford R; Raftery M; Hough S; Buckland G; Bailey M; Ghodke Y; Absar N; Vaughan L; Pasalic L; Fong CY; Kenealy M; Hiwase D; Stoddart R; Mohammed S; Lee L; Passam FH; Spring K; Skarratt KK; Rebeiro P; Larsen SR; Presgrave P; Stevenson WS; Ling S; Tiley C; Fuller S; Roncolato F; Enjeti AK; Hoenemann D; Lemech C; Bohlander SK; Olivier J; Hertzberg M; Unnikrishnan A; Polizzotto MN, 2022, 'In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial', Blood, 140, pp. 6927 - 6929, http://dx.doi.org/10.1182/blood-2022-157634
    Journal articles | 2022
    Wynne C; Schwabe C; Lemech C; Stroissnig H; Dias R; Sobierska J; Guenzi E; Otto H; Sattar A; Kay R; Haliduola HN; Berti F, 2022, 'A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST)', Expert Opinion on Investigational Drugs, 31, pp. 965 - 976, http://dx.doi.org/10.1080/13543784.2022.2035359
    Journal articles | 2022
    Lee DH; Roohullah A; Cho BC; Lee S-H; Lemech C; De Souza P; Millward M; Choi J; Park KE; Kim E; Kim NY; Shin YK; Han J-Y, 2022, 'A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation', ANNALS OF ONCOLOGY, vol. 33, pp. S1096 - S1096, http://dx.doi.org/10.1016/j.annonc.2022.07.1320
    Journal articles | 2021
    Coward J; Frentzas S; Mislang A; Gao B; Lemech C; Jin X; Li B; Wang M; Kwek KY; Zhou Y; Xia Y, 2021, '427 Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study', Regular and Young Investigator Award Abstracts, pp. A457 - A457, http://dx.doi.org/10.1136/jitc-2021-sitc2021.427
    Journal articles | 2021
    Coward J; Mislang ARA; Frentzas S; Lemech CR; Nagrial A; Jin X; Li B; Wang ZM; Kwek KY; Xia Y, 2021, 'Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.', Journal of Clinical Oncology, 39, pp. 2515 - 2515, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.2515
    Journal articles | 2021
    Lee DH; Roohullah A; Cho BC; Lemech C; de Souza P; Millward M; Choi J; Park KE; Lee M; Kim Y; Park S; Lee J; Kim J; Shin YK; Han J-Y, 2021, 'Phase I dose-escalation study to evaluate safety and clinical activity of c-MET inhibitor ABN401 in patients with advanced solid tumor', ANNALS OF ONCOLOGY, 32, pp. S1029 - S1030, http://dx.doi.org/10.1016/j.annonc.2021.08.1958
    Journal articles | 2021
    Lee DH; Roohullah A; Cho BC; Lemech CR; de Souza PL; Millward M; Choi JY; Park KE; Lee M; Kim Y; Shin Y; Han J-Y, 2021, 'Trial in progress: A phase 1-2 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors.', JOURNAL OF CLINICAL ONCOLOGY, 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.TPS3157
    Journal articles | 2021
    Lemech CR; Kichenadasse G; Marschner J-P; Alevizopoulos K; Otterlei M; Millward M, 2021, 'Safety profile and disease stabilization in late stage, heavily pretreated, solid tumor patients in a first-in-human (FIH) study of ATX-101, a drug targeting proliferating cell nuclear antigen (PCNA).', Journal of Clinical Oncology, 39, pp. 3067 - 3067, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.3067
    Journal articles | 2021
    Lickliter JD; Jennens R; Lemech CR; Kichenadasse G; Cai D; Su SY-C, 2021, 'Phase 1 dose-escalation study of ACT001 in patients with recurrent glioblastoma and other advanced solid tumors.', Journal of Clinical Oncology, 39, pp. 2037 - 2037, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.2037
    Journal articles | 2020
    Coward J; Lemech CR; Mislang ARA; Parakh S; Underhill C; Nagrial A; Jin X; Li B; Wang ZM; Kwek KY; Xia Y, 2020, 'A phase I study of AK112, a bispecific antibody that targets PD-1 and VEGF co-expressing T cells, in patients with advanced solid tumors.', Journal of Clinical Oncology, 38, pp. TPS3155 - TPS3155, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps3155
    Journal articles | 2020
    Lemech C; Woodward N; Chan N; Mortimer J; Naumovski L; Nuthalapati S; Tong B; Jiang F; Ansell P; Ratajczak CK; Sachdev J, 2020, 'A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors', Investigational New Drugs, 38, pp. 1815 - 1825, http://dx.doi.org/10.1007/s10637-020-00960-z
    Journal articles | 2020
    Perry N; Moss S; Dixon S; Milner S; Mokbel K; Lemech C; Arkenau HT; Duffy S; Pinker K, 2020, 'Mammographic breast density and urbanization: Interactions with BMI, environmental, lifestyle, and other patient factors', Diagnostics, 10, http://dx.doi.org/10.3390/diagnostics10060418
    Journal articles | 2019
    Berry S; Giraldo N; Nguyen P; Green B; Xu H; Ogurtsova A; Soni A; Succaria F; Wang D; Roberts C; Stein J; Engle E; Pardoll D; Anders R; Cottrell T; Taube JM; Tran B; Voskoboynik M; Kuo J; Bang YL; Chung HC; Ahn MJ; Kim SW; Perera A; Freeman D; Achour I; Faggioni R; Xiao F; Ferte C; Lemech C; Meric-Bernstam F; Werner T; Hodi S; Messersmith W; Lewis N; Talluto C; Dostalek M; Tao A; McWhirter S; Trujillo D; Luke J; Xu C; Bomarelli B; Qi J; Qin G; Yu H; Jenkins M; Lo KM; Halle JP; Lan Y; Taylor M; Vogelzang N; Cohn A; Stepan D; Shumaker R; Dutcus C; Guo M; Schmidt E; Rasco D; Brose M; Di Simone C; Jain S; Richards D; Encarnacion C; Vogelzeng N; Mier J; An J; Yang YY; Lee WH; Yang J; Kim JK; Kim HG; Paek SH; Lee JW; Woo J; Kim JB; Kwon H; Lim W; Paik NS; Kim YK; Moon BI; Janku F; Tan D; Martin-Liberal J; Takahashi S; Geva R; Gucalp A; Chen X; Subramanian K; Mataraza J; Wheler J; Bedard P, 2019, 'Correction: 33rd Annual meeting & pre-conference programs of the Society for Immunotherapy of Cancer (SITC 2018) (Journal for ImmunoTherapy of Cancer (2018) 6:Suppl 1 DOI: 10.1186/s40425-018-0422-y)', Journal for ImmunoTherapy of Cancer, 7, http://dx.doi.org/10.1186/s40425-019-0519-y
    Journal articles | 2018
    Coward J; Lemech C; Meniawy T; Dupont CD; Gonzalez AM; Lim M; Savitsky D; Carini M; Hu S; Shebanova O; Dow E; Ortuzar W; Buell JS; Stein RB; Youssoufian H, 2018, 'Phase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors', Annals of oncology : official journal of the European Society for Medical Oncology, 29, pp. viii417, http://dx.doi.org/10.1093/annonc/mdy288.041
    Journal articles | 2018
    Lickliter JD; Jennens R; Lemech CR; Su SY-C; Chen Y, 2018, 'Phase 1 dose-escalation study of ACT001 in patients with recurrent glioblastoma and other advanced solid tumors', JOURNAL OF CLINICAL ONCOLOGY, 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.e14048
    Journal articles | 2017
    Goldstein D; Lemech C; Valle J, 2017, 'New molecular and immunotherapeutic approaches in biliary cancer', ESMO Open, 2, pp. e000152, http://dx.doi.org/10.1136/esmoopen-2016-000152
    Journal articles | 2017
    Mateo J; Ganji G; Lemech C; Burris HA; Han SW; Swales K; Decordova S; DeYoung MP; Smith DA; Kalyana-Sundaram S; Wu J; Motwani M; Kumar R; Tolson JM; Rha SY; Chung HC; Eder JP; Sharma S; Bang YJ; Infante JR; Yan L; De Bono JS; Arkenau HT, 2017, 'A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors', Clinical Cancer Research, 23, pp. 5981 - 5992, http://dx.doi.org/10.1158/1078-0432.CCR-17-0725
    Journal articles | 2017
    Uccello M; Moschetta M; Mak G; Martynyuk N; Hauser J; Bassett S; Voskoboynik M; Lemech C; Rafii S; Arkenau H-T, 2017, 'BRAF +/- MEK inhibition in patients (pts) with BRAF-mutant (mut) metastatic colorectal cancer (mCRC): The Sarah Cannon Research Institute UK’s experience.', Journal of Clinical Oncology, 35, pp. 645 - 645, http://dx.doi.org/10.1200/jco.2017.35.4_suppl.645
    Journal articles | 2016
    Bendell JC; Patel MR; Yoshida K; Seraj J; Weaver R; Lemech C; Todaro TG; Pant S; Arkenau HT, 2016, 'Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors', Cancer Chemotherapy and Pharmacology, 77, pp. 1275 - 1283, http://dx.doi.org/10.1007/s00280-016-3031-9
    Journal articles | 2016
    Hughes A; Landers D; Arkenau HT; Shah S; Stephens R; Mahal A; Simmons M; Lemech C; Royle J, 2016, 'Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT', Advances in Therapy, 33, pp. 1012 - 1024, http://dx.doi.org/10.1007/s12325-016-0335-4
    Journal articles | 2016
    Hughes A; Landers D; Arkenau HT; Shah S; Stephens R; Mahal A; Simmons M; Lemech C; Royle J, 2016, 'Erratum to: Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT (Adv Ther, (2016), 33, (1012-1024), 10.1007/s12325-016-0335-4)', Advances in Therapy, 33, pp. 1677 - 1678, http://dx.doi.org/10.1007/s12325-016-0390-x
    Journal articles | 2016
    Lemech CR; Ensell L; Paterson JC; Eminowicz G; Lowe H; Arora R; Arkenau HT; Widschwendter M; MacDonald N; Olaitan A; Mould T; Meyer T; Hartley J; Mitra A; Ledermann JA; McCormack M; Kristeleit RS, 2016, 'Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer', Oncology (Switzerland), 91, pp. 48 - 54, http://dx.doi.org/10.1159/000445999
    Journal articles | 2016
    Lemech CR; Williams R; Thompson SR; McCaughan B; Chin M, 2016, 'Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: A case report', BMC Research Notes, 9, pp. 386, http://dx.doi.org/10.1186/s13104-016-2189-x
    Journal articles | 2016
    Plesner T; Arkenau HT; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; De Boer C; Khokhar NZ; Yeh H; Clemens PL; Ahmadi T; Lokhorst HM; Richardson PG, 2016, 'Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma', Blood, 128, pp. 1821 - 1828, http://dx.doi.org/10.1182/blood-2016-07-726729
    Journal articles | 2016
    Soria JC; Gan HK; Blagden SP; Plummer R; Arkenau HT; Ranson M; Evans TRJ; Zalcman G; Bahleda R; Hollebecque A; Lemech C; Dean E; Brown J; Gibson D; Peddareddigari V; Murray S; Nebot N; Mazumdar J; Swartz L; Auger KR; Fleming RA; Singh R; Millward M, 2016, 'A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors', Annals of Oncology, 27, pp. 2268 - 2274, http://dx.doi.org/10.1093/annonc/mdw427
    Journal articles | 2015
    Laille E; Patel M; Jones SF; Burris HA; Infante J; Lemech C; Liu L; Arkenau HT, 2015, 'Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer', Journal of Clinical Pharmacology, 55, pp. 1378 - 1385, http://dx.doi.org/10.1002/jcph.560
    Journal articles | 2015
    Lemech C; Dua D; Newmark J; Saggese M; Simmons E; Spiliopoulou P; Arkenau HT, 2015, 'Patients' perceptions of research biopsies in phase i oncology trials', Oncology (Switzerland), 88, pp. 95 - 102, http://dx.doi.org/10.1159/000368161
    Journal articles | 2014
    Hillman RJ; Garland SM; Gunathilake MPW; Stevens M; Kumaradevan N; Lemech C; Ward RL; Meagher A; McHugh L; Jin F; Carroll S; Goldstein D; Grulich AE; Tabrizi SN, 2014, 'Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers', International Journal of Cancer, 135, pp. 996 - 1001, http://dx.doi.org/10.1002/ijc.28730
    Journal articles | 2014
    Plesner T; Arkenau H-T; Lokhorst HM; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Ahmadi T; Yeh H; Guckert ME; Feng H; Brun NC; Lisby S; Basse L; Palumbo A; Richardson PG, 2014, 'Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma', BLOOD, 124, http://dx.doi.org/10.1182/blood.V124.21.84.84
    Journal articles | 2013
    Baird RD; Cresti N; Beddowes E; Saggese M; Flynn M; Corbacho JG; Gao F; Lemech C; Donaldson K; Posner J; Kawabata I; Forster M; Arkenau HT; Plummer R; Jodrell D; Spicer J, 2013, 'Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancer', CANCER RESEARCH, 73, http://dx.doi.org/10.1158/0008-5472.SABCS13-P4-12-24
    Journal articles | 2013
    Jones A; Teschendorff AE; Li Q; Hayward JD; Kannan A; Mould T; West J; Zikan M; Cibula D; Fiegl H; Lee SH; Wik E; Hadwin R; Arora R; Lemech C; Turunen H; Pakarinen P; Jacobs IJ; Salvesen HB; Bagchi MK; Bagchi IC; Widschwendter M, 2013, 'Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development', PLoS Medicine, 10, http://dx.doi.org/10.1371/journal.pmed.1001551
    Journal articles | 2013
    Lemech C; Infante J; Arkenau HT, 2013, 'Combination molecularly targeted drug therapy in metastatic melanoma: Progress to date', Drugs, 73, pp. 767 - 777, http://dx.doi.org/10.1007/s40265-013-0049-8
    Journal articles | 2013
    Lemech CR; Arkenau HT, 2013, 'Rationally Designed Drug Development beyond BRAF Inhibition in Metastatic Cutaneous Melanoma', World Journal of Cancer Research
    Journal articles | 2013
    Lemech CR; Arkenau HT, 2013, 'The future is here: Tumour profiling in day-to-day clinical practice', Drug Discovery Today, 18, pp. 689 - 691, http://dx.doi.org/10.1016/j.drudis.2013.06.006
    Journal articles | 2013
    Saggese M; Dua D; Simmons E; Lemech C; Arkenau H-T, 2013, 'Research biopsies in the context of early phase oncology studies: clinical and ethical considerations', Oncology Reviews, pp. e5 - e5, http://dx.doi.org/10.4081/oncol.2013.232
    Journal articles | 2013
    Saggese M; Dua D; Simmons E; Lemech C; Arkenau HT, 2013, 'Research biopsies in the context of early phase oncology studies: Clinical and ethical considerations', Oncology Reviews, 7, pp. 34 - 37, http://dx.doi.org/10.4081/oncol.2013.e5
    Journal articles | 2012
    Arkenau H-T; Saggese M; Lemech C, 2012, 'DABRAFENIB MESYLATE Serine/Threonine-Protein Kinase B-raf Inhibitor, Oncolytic', DRUGS OF THE FUTURE, 37, pp. 469 - 474, http://dx.doi.org/10.1358/dof.2012.037.07.1820872
    Journal articles | 2012
    Arkenau H-T; Saggese M; Lemech C, 2012, 'Dabrafenib. Serine/threonine-protein kinase B-raf inhibitor, Oncolitic.', Drugs of the Future, 37, pp. 469 - 469, http://dx.doi.org/10.1358/dof.2012.37.7.1820872
    Journal articles | 2012
    Arkenau HT; Saggese M; Lemech C, 2012, 'Advanced gastric cancer: Is there enough evidence to call second-line therapy standard?', World Journal of Gastroenterology, 18, pp. 6376 - 6378, http://dx.doi.org/10.3748/wjg.v18.i44.6376
    Journal articles | 2012
    Arkenau HT; Saggese M; Lemech C, 2012, 'Dabrafenib mesylate: Serine/threonine-protein kinase B-raf inhibitor oncolytic', Drugs of the Future, 37, pp. 469 - 474, http://dx.doi.org/10.1358/dof.2012.037.07.1820872
    Journal articles | 2012
    Lemech C; Arkenau HT, 2012, 'Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities', Clinical Medicine Insights: Oncology, 6, pp. 53 - 66, http://dx.doi.org/10.4137/CMO.S5855
    Journal articles | 2012
    Lemech C; Infante J; Arkenau HT, 2012, 'The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: Rationale and latest evidence', Therapeutic Advances in Medical Oncology, 4, pp. 61 - 73, http://dx.doi.org/10.1177/1758834011432949
    Journal articles | 2012
    Lemech CR; Fontela A; Arkenau H-T; Chin MTM; Li S; Liauw WS; Thomas D; De Souza PL, 2012, 'Phase I study of everolimus in combination with fluvastatin and zoledronic acid in patients with solid tumours.', Journal of Clinical Oncology, 30, pp. e13585 - e13585, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e13585
    Journal articles | 2012
    Soria J-C; Gan HK; Arkenau H-T; Blagden SP; Plummer R; Ranson M; Evans TRJ; Zalcman G; Bahleda R; Hollebecque A; Lemech C; Brown J; Peddareddigari VGR; Gibson D; Murray SC; Nebot N; Mazumdar J; Fleming RA; Millward M, 2012, 'Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.', Journal of Clinical Oncology, 30, pp. 3000 - 3000, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.3000
    Journal articles | 2011
    Anglesio M; Kulbe H; Friedlander M; Rischin D; Lemech C; Power J; Coward J; Cowin P; House CM; Chakravarty P; Gorringe K; Campbell I; George J, 2011, 'IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.', Clinical Cancer Research, 17, pp. 2538 - 2548
    Journal articles | 2011
    Lemech C; Arkenau HT, 2011, 'Biomarkers in advanced colorectal cancer: Challenges in translating clinical research into practice', Cancers, 3, pp. 1844 - 1860, http://dx.doi.org/10.3390/cancers3021844
  • Conference Papers | 2024
    Fu S; Mckean M; Falchook GS; Barve M; Chee C-E; Lemech C; Tan TJ; Meniawy T; Hernandez-Guerrero T; Wang W; Baakili A; Marina N; Abbadessa G; Gastine S; Wang R; Calvo E, 2024, '196 Utilizing pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers to support recommended phase 2 dose (RP2D) selection for phase 1 study of SAR444245 (SAR’245) in patients with advanced solid tumors', in Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, pp. A224 - A224, presented at SITC 39th Annual Meeting (SITC 2024) Abstracts, http://dx.doi.org/10.1136/jitc-2024-sitc2024.0196
    Conference Papers | 2023
    To MD; Merchant R; Atkinson V; Bedard P; Brenner W; Coello M; Antras JF; Galligan C; Lemech C; Lloyd P; Karanam SM; Margolin K; Mathew M; Prawira A; Thomas S; Twardowski P; Yavari A; Merchant F, 2023, '760 Interim PK/PD, safety and efficacy data of monotherapy dose escalation of a phase 1/2 study with MDNA11 in patients with advanced solid tumors', in Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, pp. A856 - A856, presented at SITC 38th Annual Meeting (SITC 2023) Abstracts, http://dx.doi.org/10.1136/jitc-2023-sitc2023.0760
    Conference Abstracts | 2022
    Lee DH; Roohullah A; Cho BC; Lee S-H; Lemech C; De Souza P; Millward M; Choi J; Park KE; Kim E; Kim NY; Shin YK; Han J-Y, 2022, 'A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 33, pp. S1096 - S1096, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022, http://dx.doi.org/10.1016/j.annonc.2022.07.1320
    Conference Abstracts | 2022
    Lee DH; Roohullah A; Cho BC; Lemech CR; de Souza PL; Millward M; Choi JY; Park KE; Kim NY; Kim E; Lee S; Kim Y; Shin YOUNGKEE; Han J-Y, 2022, 'A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3105 - 3105, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3105
    Conference Abstracts | 2022
    Strickler JH; Satake H; Hollebecque A; Sunakawa Y; Tomasini P; Bajor DL; Schuler MH; Yaeger R; George TJ; Garrido-Laguna I; Coveler AL; Vincent MD; Falchook GS; Burns TF; Rha SY; Lemech CR; Juric D; Jafarinasabian P; Tran Q; Hong DS, 2022, 'First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 360490 - 360490, http://dx.doi.org/10.1200/jco.2022.40.36_suppl.360490
    Conference Papers | 2022
    To M; Merchant F; Atkinson V; Bexon M; Coward J; Lee J; Lemech C; Antras J; Lloyd P; Yavari A; Coello M; Merchant N, 2022, '744 Interim single-agent safety and anti-tumor activity from dose escalation phase of ABILITY study on MDNA11, a long-acting beta-only IL-2 agonist', in Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, pp. A777 - A777, presented at SITC 37th Annual Meeting (SITC 2022) Abstracts, http://dx.doi.org/10.1136/jitc-2022-sitc2022.0744
    Conference Papers | 2022
    To M; Merchant N; Coello M; Galligan C; Mehta K; Atkinson V; Bexon M; Coward J; Lee J; Lemech C; Lloyd P; Antras J; Yavari A; Merchant F, 2022, '743 Pharmacokinetic and pharmacodynamic profile of a first-in-human study with MDNA11, an engineered long-acting beta-only IL-2 agonist', in Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, pp. A776 - A776, presented at SITC 37th Annual Meeting (SITC 2022) Abstracts, http://dx.doi.org/10.1136/jitc-2022-sitc2022.0743
    Conference Abstracts | 2022
    Tran B; Voskoboynik M; Kim S-W; Lemech C; Carcereny E; Rha SY; Ahn M-J; Felip E; Lee KH; Alvarez EC; Yang JC-H; Ascierto PA; Pulla MP; Freeman D; Song X; Gainer SD; Mitchell P; Achour I; Subramaniam DS; Im S-A, 2022, 'Abstract CT016: MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors: First-in-human study', in Cancer Research, American Association for Cancer Research (AACR), Vol. 82, pp. CT016 - CT016, http://dx.doi.org/10.1158/1538-7445.am2022-ct016
    Conference Papers | 2021
    Lemech C; Dredge K; Bampton D; Hammond E; Clouson A; Waterhouse N; Stanley A; Leveque-ElMouttie L; Chojnowski G; Haydon A; Pavlakis N; Burge M; Brown M; Goldstein D, 2021, 'A PHASE IB EXPANSION COHORT OF PIXATIMOD PLUS NIVOLUMAB IN PREVIOUSLY TREATED, MICROSATELLITE STABLE METASTATIC COLORECTAL CANCER (MSS MCRC)', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A367 - A367, http://dx.doi.org/10.1136/jitc-2021-SITC2021.341
    Conference Papers | 2021
    Lemech C; Dredge K; Bampton D; Hammond E; Stanley A; Leveque-ElMouttie L; Chojnowski G; Haydon A; Pavlakis N; Burge M; Brown M; Goldstein D, 2021, 'A PHASE IB STUDY OF THE SAFETY AND TOLERABILITY OF PIXATIMOD PLUS NIVOLUMAB IN SUBJECTS WITH ADVANCED SOLID TUMORS WITH AN EXPANSION COHORT IN METASTATIC PANCREATIC ADENOCARCINOMA (MPDAC)', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A366 - A366, http://dx.doi.org/10.1136/jitc-2021-SITC2021.340
    Preprints | 2020
    Gavagna G; Clifton-Bligh R; Lemech C; Williams S; Elefantis E; Nair H; Farrugia A, 2020, Intravenous Immunoglobulin Rich in Neutralising Antibodies to SARS-CoV-2 as a Passive Immunity Modality in Healthy Individuals at Risk of Infection With COVID-19: Study Protocol for an Open Label, Active Control Phase 1/2 Study., http://dx.doi.org/10.21203/rs.3.rs-137186/v1
    Conference Abstracts | 2020
    Markman B; Day D; Park JJW; Coward J; Bishnoi S; Kotasek D; Eek R; Brown MP; Lemech C; Kuo J; Prawira A; Strother R; Zhang Q; Wang L; Chen R; Ma Y; Qin Z; Tse A, 2020, 'Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 31, pp. S722 - S722, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.1177
    Conference Papers | 2020
    Tran B; Horvath L; Dorff T; Rettig M; Lolkema MP; Machiels J-P; Rottey S; Autio K; Greil R; Adra N; Lemech C; Minocha M; Cheng F-C; Kouros-Mehr H; Fizazi K, 2020, 'Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE (R)) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S507 - S507, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.869
    Conference Papers | 2019
    Unnikrishnan A; Lim XY; Joshi S; Nunez AC; Vaughan L; Pickford R; Hough S; Davidson S; Fong C; Kenealy M; Hiwase DK; Pasalic L; Mohammed S; Lee L; Passam FH; Spring K; Rebeiro P; Ling S; Fuller S; Presgrave P; Roncolato F; Larsen S; Enjeti AK; Stevenson WS; Tiley C; Campbell PJ; Lemech C; Olivier J; Hertzberg M; Polizzotto MN; Pimanda J, 2019, 'In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, presented at 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), FL, Orlando, 07 December 2019 - 10 December 2019, http://dx.doi.org/10.1182/blood-2019-123921
    Conference Papers | 2018
    Kuo J; Bampton D; Lemech CR; Brown MP; Stanley A; Chojnowski G; Hammond E; Dredge K; Goldstein D, 2018, 'Preliminary results from a Phase Ib study of pixatimod (PG545) in combination with nivolumab in patients with advanced solid tumours with an expansion cohort in patients with metastatic pancreatic cancer', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, IRELAND, Dublin, pp. E18 - E19, presented at 30th EORTC-NCI-AACR Symposium, IRELAND, Dublin, 13 November 2018 - 16 November 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000461258600037&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2018
    Kuo JC; Roncolato FT; Bahari B; Wharton J; Lemech CR, 2018, 'Conducting early-phase oncology clinical trials: Experience of a dedicated clinical trial unit', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 154 - 155, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449544200254&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2015
    Plesner T; Arkenau H-T; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; Yeh H; Ahmadi T; Lokhorst HM; Richardson PG, 2015, 'Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, presented at 57th Annual Meeting of the American-Society-of-Hematology, FL, Orlando, 05 December 2015 - 08 December 2015, http://dx.doi.org/10.1182/blood.V126.23.507.507
    Conference Papers | 2014
    Arkenau H-T; Mateo J; Lemech CR; Infante JR; Burris HA; Bang Y-J; Eder JP; Herbst RS; Sharma S; Chung HC; Decordova S; Swales KE; Garrett MD; Loftiss JI; Durante M; Russo MW; Suttle BB; Motwani M; Kumar R; De Bono JS, 2014, 'A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.2514
    Conference Papers | 2014
    Arkenau H-T; Saggese M; Hollebecque A; Mathewson A; Lemech CR; Landers D; Frewer P; Kilgour E; Brooks N, 2014, 'A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.2620
    Conference Papers | 2014
    Lemech CR; Ensell L; Paterson J; Eminowicz G; Lowe H; Griffin N; Arora R; Arkenau H-T; Widschwendter M; MacDonald N; Olaitan A; Mould T; Meyer T; Hartley JA; Mitra A; Ledermann JA; McCormack M; Kristeleit RS, 2014, 'Feasibility of circulating tumour cell (CTC) enumeration and molecular profiling (MP) as a biomarker in advanced endometrial cancer (aEC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.5600
    Conference Papers | 2014
    Plesner T; Arkenau H-T; Lokhorst HM; Gimsing P; Krejcik J; Lemech CR; Minnema M; Lassen UN; Ahmadi T; Yeh H; Guckert M; Brun NC; Lisby S; Basse L; Palumbo A; Richardson PG, 2014, 'Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.8533
    Conference Papers | 2014
    Plesner T; Arkenau HT; Lokhorst HM; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Ahmadi T; Yeh H; Guckert M; Brun NC; Lisby S; Basse L; Palumbo A; Richardson PG, 2014, 'SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, ITALY, Milan, pp. 104 - 104, presented at 19th Congress of the European-Hematology-Association, ITALY, Milan, 12 June 2014 - 15 June 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000342830900251&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2013
    Baird RD; Cresti N; Beddowes E; Saggese M; Flynn M; Garcia Corbacho J; Gao F; Lemech CR; Donaldson K; Posner J; Kawabat I; Forster M; Arkenau HT; Plummer R; Jodrell D; Spicer J, 2013, 'Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily pre-treated HER2-positive metastatic breast cancer', presented at San Antonio Breast Cancer Symposium, 10 December 2013 - 14 December 2013, http://www.abstracts2view.com/sabcs13/viewp.php?nu=P4-12-24
    Conference Posters | 2013
    Dua D; Lemech CR; Newmark J; Saggese M; Spiliopoulou P; Ash N; Williams I; Hauser J; Lauigan M; Muzengi M; Arkenau HT, 2013, 'Patients' perceptions of research biopsies on early phase oncology trials', Liverpool UK, presented at NCRI Cancer Conference, Liverpool UK, 03 November 2013 - 06 November 2013
    Conference Posters | 2013
    Ganguli S; Spiliopoulou P; Benafif S; Flynn M; Lemech CR; Saggese M; Forster M; Kristeleit R; Arkenau HT; Meyer T, 2013, 'Clinical outcomes for patients in early phase clinical trials: the UCLH and Sarah Cannon Research UK experience', Liverpool UK, presented at NCRI Cancer Conference, Liverpool UK, 03 November 2013 - 06 November 2013, http://conference.ncri.org.uk/abstracts/2013/abstracts/B65.htm
    Conference Papers | 2013
    Lemech CR; Newmark J; Arkenau H-T, 2013, 'The use of molecular profiling (MP) beyond standard panels in day-to-day practice: A multi-institutional multinational survey', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419604404&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Posters | 2013
    Lemech CR; Newmark J; Arkenau HT, 2013, 'The use of molecular profiling (MP) beyond standard panels in day-to-day practice - a multi-institutional multi-national survey', Liverpool UK, presented at NCRI Cancer Conference, Liverpool UK, 03 November 2013 - 06 November 2013, http://conference.ncri.org.uk/abstracts/2013/abstracts/B101.htm
    Conference Papers | 2013
    Plesner T; Arkenau T; Lokhorst H; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Cakana A; Brun NC; Basse L; Palumbo A; Richardson PG, 2013, 'Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma', in BLOOD, AMER SOC HEMATOLOGY, LA, New Orleans, presented at 55th Annual Meeting of the American-Society-of-Hematology, LA, New Orleans, 07 December 2013 - 10 December 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000331385004173&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2012
    Lemech C; Fontela A; Arkenau H; Chin M; Li S; Liauw WS; Thomas D; De Souza P, 2012, 'Phase I study of everolimus in combination with fluvastatin and zoledronic acid in patients with solid tumours', in Journal of clinical oncology - official journal of the American Society of Clinical Oncology, American Society of Clinical Oncology, New York, pp. e13585 - e13585, presented at ASCO Annual Meeting, Chicago, USA, 01 June 2012 - 05 June 2012, http://meeting.ascopubs.org/gca?gca=ascomtg%3B30%2F15_suppl%2Fe13585&allch=&submit=Go#abstr-1
    Conference Papers | 2012
    Soria J-C; Gan HK; Arkenau H-T; Blagden SP; Plummer R; Ranson M; Evans TRJ; Zalcman G; Bahleda R; Hollebecque A; Lemech C; Brown J; Peddareddigari VGR; Gibson D; Murray SC; Nebot N; Mazumdar J; Fleming RA; Millward M, 2012, 'Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009802283&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2010
    Lemech CR; Cosman R; Lee C; Friedlander M; Lewis C; Lynch J; Thomas D; Clingan P; Glasgow A, 2010, 'Cardiac dysfunction in patients receiving trastuzumab for early stage breast cancer in the SESIAHS', in Aisa-Pacific Journal of Clinical Oncology, Medical Oncology Group of Australia Annual Scientific Meeting, Sydney Australia, presented at Medical Oncology Group of Australia Annual Scientific Meeting, Sydney Australia, 12 August 2010 - 14 August 2010, http://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2010.01301.x/epdf
    Conference Posters | 2010
    Liauw W; Lemech CR, 2010, 'Diffuse peritoneal adenomucinosis in a patient wiht familial adenomatous polyposis', Melbourne, Victoria, Australia, presented at Clinical Oncology Society of Australia Annual Scientific Meeting, Melbourne, Victoria, Australia, 09 November 2010 - 11 November 2010
    Conference Posters | 2009
    Lemech CR; Friedlander M, 2009, 'Clear cell cancer of the ovary: from resistance to response', Canberra Australia, presented at MOGA Annual Scientific Meeting, Canberra Australia, 12 August 2009 - 14 August 2009, http://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2009.01218.x/pdf